MX2021013980A - Compuesto para el tratamiento de gota o hiperuricemia. - Google Patents
Compuesto para el tratamiento de gota o hiperuricemia.Info
- Publication number
- MX2021013980A MX2021013980A MX2021013980A MX2021013980A MX2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A MX 2021013980 A MX2021013980 A MX 2021013980A
- Authority
- MX
- Mexico
- Prior art keywords
- hyperuricemia
- compound
- gout
- treatment
- methanone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847519P | 2019-05-14 | 2019-05-14 | |
| PCT/US2020/032725 WO2020232156A1 (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013980A true MX2021013980A (es) | 2022-04-01 |
Family
ID=73288915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013980A MX2021013980A (es) | 2019-05-14 | 2020-05-13 | Compuesto para el tratamiento de gota o hiperuricemia. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220242841A1 (enExample) |
| EP (1) | EP3968989A4 (enExample) |
| JP (1) | JP7656548B2 (enExample) |
| KR (1) | KR102971948B1 (enExample) |
| CN (1) | CN113874014A (enExample) |
| AU (2) | AU2020274165A1 (enExample) |
| BR (1) | BR112021022843A2 (enExample) |
| CA (1) | CA3140412A1 (enExample) |
| IL (1) | IL288034B2 (enExample) |
| MA (1) | MA55973A (enExample) |
| MX (1) | MX2021013980A (enExample) |
| SG (1) | SG11202112562XA (enExample) |
| TW (1) | TW202108561A (enExample) |
| WO (1) | WO2020232156A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164439A (zh) | 2018-12-06 | 2021-07-23 | 安索治疗公司 | 用于治疗或预防痛风或高尿酸血症的方法 |
| JP2022511800A (ja) | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| WO2023058975A1 (ko) * | 2021-10-07 | 2023-04-13 | (주)이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
| WO2023098872A1 (en) * | 2021-12-02 | 2023-06-08 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
| US20250242050A1 (en) | 2024-01-31 | 2025-07-31 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| AU2017298142B2 (en) * | 2016-07-18 | 2021-11-11 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| JP2022511800A (ja) * | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
-
2020
- 2020-05-13 CA CA3140412A patent/CA3140412A1/en active Pending
- 2020-05-13 JP JP2021568229A patent/JP7656548B2/ja active Active
- 2020-05-13 SG SG11202112562XA patent/SG11202112562XA/en unknown
- 2020-05-13 US US17/610,673 patent/US20220242841A1/en not_active Abandoned
- 2020-05-13 MA MA055973A patent/MA55973A/fr unknown
- 2020-05-13 KR KR1020217041035A patent/KR102971948B1/ko active Active
- 2020-05-13 AU AU2020274165A patent/AU2020274165A1/en not_active Abandoned
- 2020-05-13 BR BR112021022843A patent/BR112021022843A2/pt unknown
- 2020-05-13 EP EP20804806.6A patent/EP3968989A4/en active Pending
- 2020-05-13 MX MX2021013980A patent/MX2021013980A/es unknown
- 2020-05-13 CN CN202080035809.1A patent/CN113874014A/zh active Pending
- 2020-05-13 WO PCT/US2020/032725 patent/WO2020232156A1/en not_active Ceased
- 2020-05-13 TW TW109115899A patent/TW202108561A/zh unknown
-
2021
- 2021-11-11 IL IL288034A patent/IL288034B2/en unknown
-
2026
- 2026-03-12 US US19/565,114 patent/US20260200884A1/en active Pending
- 2026-03-23 AU AU2026202224A patent/AU2026202224A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL288034A (en) | 2022-01-01 |
| AU2026202224A1 (en) | 2026-04-09 |
| CA3140412A1 (en) | 2020-11-19 |
| JP2022533958A (ja) | 2022-07-27 |
| BR112021022843A2 (pt) | 2022-03-03 |
| EP3968989A1 (en) | 2022-03-23 |
| SG11202112562XA (en) | 2021-12-30 |
| IL288034B1 (en) | 2026-04-01 |
| AU2020274165A1 (en) | 2022-01-06 |
| US20260200884A1 (en) | 2026-07-16 |
| KR20220016105A (ko) | 2022-02-08 |
| IL288034B2 (en) | 2026-08-01 |
| TW202108561A (zh) | 2021-03-01 |
| US20220242841A1 (en) | 2022-08-04 |
| JP7656548B2 (ja) | 2025-04-03 |
| KR102971948B1 (ko) | 2026-06-01 |
| WO2020232156A1 (en) | 2020-11-19 |
| CN113874014A (zh) | 2021-12-31 |
| MA55973A (fr) | 2022-03-23 |
| EP3968989A4 (en) | 2022-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022843A2 (pt) | Composto para tratamento de gota ou hiperuricemia | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| AR122380A1 (es) | Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| CR20170605A (es) | DERIVADOS DE 3-TETRAZOLIL-BENCENO-1,2-DISULFONAMIDA COMO INHIBIDORES DE METALO -ß-LACTAMASA | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| EA202191543A1 (ru) | Способы лечения или профилактики подагры или гиперурикемии | |
| FI3661510T3 (fi) | Menetelmiä käyttäytymismuutosten hoitamiseksi | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| MX2018014080A (es) | Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. | |
| MX2022004808A (es) | Métodos para tratar el cáncer de próstata. | |
| MX389330B (es) | Metodo de tratamiento de afecciones relacionadas con el receptor pgi2. | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2025009866A (es) | Metodos de uso de inhibidores del factor b | |
| CL2022001314A1 (es) | Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| BR112022022628A2 (pt) | Inibidor de dhodh para o tratamento de covid-19 | |
| MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. |